Inj, tyenne, 1 mg
Products billed under this code include Tyenne.
Payment limit per 1 MG, by effective quarter, 1Q25 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.Products billed under this code include Tyenne.
Payment limit per 1 MG, by effective quarter, 1Q25 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.From the 4Q26 NDC–HCPCS crosswalk. “Limit / pkg” is the 4Q26 payment limit times the billing units in one package.
| Product | Labeler | NDC | Units / pkg | Limit / pkg |
|---|---|---|---|---|
| Tyenne | FreseniUS Kabi USA, LLC | 65219-0584-01 | 162 | $707.94 |
| Tyenne | FreseniUS Kabi USA, LLC | 65219-0586-04 | 162 | $707.94 |
| Tyenne | FreseniUS Kabi USA, LLC | 65219-0590-04 | 80 | $349.60 |
| Tyenne | FreseniUS Kabi USA, LLC | 65219-0592-10 | 200 | $874.00 |
| Tyenne | FreseniUS Kabi USA, LLC | 65219-0594-20 | 400 | $1,748.00 |
| Quarter | Payment limit | Change | Billing unit | Description | Source file |
|---|---|---|---|---|---|
| 4Q26 | $4.37 | +$0.314 | 1 MG | Inj, tyenne, 1 mg | v1, posted September 17, 2026 |
| 3Q26 | $4.056 | −$0.38 | 1 MG | Inj, tyenne, 1 mg | v1, posted September 15, 2026 |
| 2Q26 | $4.436 | +$0.242 | 1 MG | Inj, tyenne, 1 mg | v1, posted September 15, 2026 |
| 1Q26 | $4.194 | −$0.221 | 1 MG | Inj, tyenne, 1 mg | v1, posted September 15, 2026 |
| 4Q25 | $4.415 | −$0.274 | 1 MG | Inj, tyenne, 1 mg | v1, posted September 8, 2026 |
| 3Q25 | $4.689 | +$0.624 | 1 MG | Inj, tyenne, 1 mg | v1, posted March 10, 2026 |
| 2Q25 | $4.065 | −$0.041 | 1 MG | Inj, tyenne, 1 mg | v1, posted March 10, 2026 |
| 1Q25 | $4.106 | – | 1 MG | Inj, tyenne, 1 mg | v1, posted December 19, 2025 |
“Change” is the difference from the previous quarter, shown only when both quarters have a payment limit and the billing unit is the same. “vs. last quarter” and “vs. a year ago” follow the same rule.